期刊
JOURNAL OF DIABETES AND ITS COMPLICATIONS
卷 29, 期 6, 页码 846-851出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2015.04.005
关键词
Diabetes mellitus; Platelets; Sulfonylureas; Metformin; Glitazones; Incretins
资金
- Eli-Lilly
- Sanofi
- Boehringer Ingelheim
- MSD
- TrigoCare International
- Novo Nordisk
- Sanofi-Aventis
- Pfizer
- Novartis
- AstraZeneca
- Libytech
- Wyeth
- Bayer
Platelet dysfunction plays a role in diabetic macrovascular complications. Several studies have assessed the effect of oral hypoglycemic agents (OHAs) on platelet function. Data from both in vivo and in vitro studies show a favorable effect for most of the traditional glucose-lowering therapies, while evidence is limited for the newer ones. Metformin, sulfonylureas, glitazones and acarbose exert a favorable effect on platelet function. Among incretin therapies, only sitagliptin has so far been demonstrated to have a beneficial effect on platelet aggregation. More in vivo and in vitro evidence is required to increase our knowledge on any potential beneficial effects of OHAs on platelet function. Any such effect may have implications for the reduction of cardiovascular risk in type 2 diabetes mellitus. (C) 2015 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据